Company profile
Charles River Laboratories International, Inc.
NYSE: CRL · Healthcare · Medical - Diagnostics & Research
#71 of 1,422 Healthcare companies by revenue40th-percentile growth
EA Score
73BFH 72DQ 78GM 56SS 92
v0.1 · 65/100 weight · provisional
↑ workforce scale, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$4.0B
Rev growth YoY (TTM)
+0.1%
Net income (FY)
-$144.3M
Employees
19,700
as of 2026-08-06
Market cap
$12.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.0B$4.0B2025
Net income-$144.3M-$144.3M2025
Operating income$25.2M$25.2M2025
Total assets$7.1B$7.1B2025
Liabilities$3.9B$3.9B2025
Equity$3.2B$3.2B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Discovery and Safety Assessment60%
Research Models and Services21%
Manufacturing Support19%
By geography
UNITED STATES54%
Europe28%
CANADA13%
Asia Pacific5%
The read
What is Charles River Laboratories International, Inc.’s revenue?
Charles River Laboratories International, Inc. booked $4.0B in FY2025 revenue, contracting 0.9% year over year — about the middle of the pack among Healthcare companies we track, at a -3.6% net margin.
Peers · Healthcare
The Cooper Companies, Inc.86AAlign Technology, Inc.83B+Mettler-Toledo International Inc.80B+Alignment Healthcare, Inc.71BAptarGroup, Inc.87AAlnylam Pharmaceuticals, Inc.79B+Neighbors
Middlesex →Key facts
CEOBirgit Girshick
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersWilmington, MA
ExchangeNYSE: CRL
Employees19,700
IPO date2000-06-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.